VitriVax, Inc.

BOULDER, Colo.--(BUSINESS WIRE)--VitriVax, Inc., a vaccine formulation technology company, today announced it has been awarded a two-year, $9.9 million grant from the Gates Foundation. The funding will support the scale-up of VitriVax’s Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology, enabling Phase 1-ready GMP manufacturing and advancing the platform to prepare for Phase 1 clinical trials. Building GMP-compliant manufacturing capacity for innovative vaccine technologies is critical to ensuring that safe, effective vaccines can reach people around the globe. Within the scope of this grant, VitriVax will work with a Contract Development and Manufacturing Organization (CDMO) suited for early-phase clinical production. The work includes preparation and execution of manufacturing and regulatory activities in support of future clinical development of an ALTA®-enabled vaccine. “This grant enables us to take ALTA® from lab-scale innovation to Phase 1-ready GMP manufacturing, an essential step toward broader access to next-generation vaccines,” said Romulo Colindres, Chief Executive Officer of VitriVax. “Building GMP-compliant manufacturing capacity for innovative vaccine technologies is critical to ensuring that safe, effective vaccines can reach people around the globe. By working with a CDMO partner, we are not only preparing for first-in-human clinical studies but also laying the groundwork for scalable, reliable production that supports global public health priorities.” ALTA® is designed to stabilize antigens and adjuvants and enable co-formulation of otherwise incompatible components, with the goal of improving vaccine utility, compatibility, and supply resilience. Scale-up and qualification activities of the ALTA® technology are intended to de-risk early clinical manufacturing and accelerate timelines from formulation to first-in-human studies. About VitriVax VitriVax, headquartered in Boulder, CO, has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology platform to enable thermostable, single-shot vaccines across a broad range of indications while maintaining or potentially even enhancing the immune response of vaccines. ALTA® can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation, enabling controlled release and incorporating prime doses and additional booster doses in a single-shot administration. These technologies may also facilitate the co-formulation of multiple, otherwise incompatible, antigens in a single injection.

BOULDER, Colo.--( BUSINESS WIRE )-- VitriVax, Inc ., a vaccine formulation technology company, announced today a two-year $3.6 million grant from the Bill & Melinda Gates Foundation. This is the second grant awarded to VitriVax by the Gates Foundation and will fund development of a polio vaccine formulation for possible inclusion in combination pediatric vaccines. VitriVax will be applying its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA ® ) technology to new polio vaccine candidates composed of virus-like particles (VLPs) for use in future combination hexavalent vaccines. Use of VLPs as a modality in polio eradication efforts is under investigation for the next generation of polio vaccines. The ALTA ® technology may facilitate the co-formulation of multiple, otherwise incompatible, antigens in a single injection. “Funding support from the Bill & Melinda Gates Foundation allows us to continue our efforts to advance global accessibility to human vaccines,” said Romulo Colindres, CEO of VitriVax. “We are honored to be part of the global drive to protect children from polio infection and contribute to polio eradication efforts.” About VitriVax VitriVax, headquartered in Boulder, CO, is a vaccine formulation technology company that engineers innovative solutions to maximize global accessibility and utility of human vaccines – vaccines that save lives and protect our world from preventable disease.

Welcome to Endpoints News ’ manufacturing news briefs, where we bring you essential updates on new builds, collaborations, recalls and more. Lonza-owned Synaffix boosted its licensing deal with Innovent Biologics on Wednesday to make at least one new ADC candidate, building upon the companies’ original deal in June 2021. Innovent will use Synaffix’s ADC manufacturing technology to develop new ADC candidates. Synaffix will receive an upfront payment as well as further milestone payments and royalties for each commercialized ADC. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.